|
Post by kc on Apr 6, 2018 16:10:16 GMT -5
All, I don’t post much but have been following the stock for years and as a physician I believe in the product and have communicated with Mike in the past about trying to bring Afrezza to the operating room. Like many of you I have lost a lot of money but I am still very hopeful and averaged down once again today... Can you expand on this comment above as several weeks ago one of our good Afrezza users and friend Hillard had Bypass surgery and was having problems getting his BG controlled in the hospital. He sent his wife home to get his Afrezza and it worked like a champ! immediately and his Doctors and Nurses were taken back by this miracle drug.
|
|
|
Post by kc on Apr 6, 2018 14:58:19 GMT -5
So it's God Friday ... and last week was Good Friday ... interesting Actually, today is also Good Friday (Eastern Rite Catholics and Orthodox). So if you were too busy and missed last week, you have another chance to celebrate Easter this Sunday. Good to know. Does anybody want my surplus Matzoh?
|
|
|
Post by kc on Apr 6, 2018 12:16:09 GMT -5
“Mannkind has about $25 million as of March 31, which means a runway until June 30” Ask yourself why Mnkd raised just enough until 6/30. Wait for the river card. Does Mike bet on the Red or Black in Monte Carlo?
|
|
|
Post by kc on Apr 6, 2018 4:13:43 GMT -5
Being over 58 you wake up in the middle the night because of needing some relief you find news like this announcement. I guess the company needed to buy some more time. Seems like they could do the $6.00 deal this time. I have to agree with the comments above that being announced pre-market Friday it will not have a positive effect trading today.
|
|
|
Post by kc on Apr 5, 2018 12:27:15 GMT -5
I was just looking at flights. Could land at LAX on the 15th at 2:50 PM. then fly back out of LAX on the 16th at 4:05 PM. Hmmm. do I do it? Anybody else flying in about the same time? Perhaps split the car rental?
|
|
|
Post by kc on Apr 5, 2018 11:56:23 GMT -5
No news. Probably just a larger short deciding to cover? A leak of upcoming event would be too much to hope for Lot of better stocks for the shorts to short these days. Easy money on Facebook or Amazon, perhaps Tesla. Better return for the parasites....
|
|
|
Post by kc on Apr 5, 2018 11:54:50 GMT -5
Yep the coffee is brewing right now......
|
|
|
Post by kc on Mar 29, 2018 16:17:14 GMT -5
Was in a meeting and was concerned it was something more than the meeting.......Thank Goodness...
MANNKIND CORPORATION 30930 Russell Ranch Road, Suite 301 Westlake Village, California 91362 (818) 661-5000 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On Wednesday, May 16, 2018
Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders of MannKind Corporation, a Delaware corporation (“MannKind”). The meeting will be held on Wednesday, May 16, 2018 at 10:00 a.m. U.S. Pacific Time at the office of MannKind at 30930 Russell Ranch Road, Suite 301, Westlake Village, California 91362 for the following purposes: 1. To elect the seven nominees named herein as directors to serve for the ensuing year and until their successors are elected; 2. To approve the MannKind Corporation 2018 Equity Incentive Plan; 3. To approve an amendment to the MannKind Corporation 2004 Employee Stock Purchase Plan to, among other things, increase the number of shares authorized for issuance under the 2004 Employee Stock Purchase Plan by 3,000,000 shares; 4. To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind’s proxy statement for the Annual Meeting; 5. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of MannKind for its fiscal year ending December 31, 2018; and 6. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. These items of business are more fully described in the proxy statement accompanying this notice. The record date for the Annual Meeting is March 19, 2018. Only stockholders of record on that date may vote at the meeting or any adjournment thereof. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders of MannKind Corporation to be Held on May 16, 2018 at 10:00 a.m. U.S. Pacific time at the office of MannKind Corporation located at 30930 Russell Ranch Road, Suite 301, Westlake Village, California 91362.
MIKE brings the avg age of the board down one or two years....
ELECTION OF DIRECTORS
MannKind’s Board of Directors consists of seven directors. There are seven nominees for director this year, all of whom were nominated by our Board of Directors. Each director to be elected will hold office until the next annual meeting of stockholders and until his successor is elected, or until the director’s earlier death, resignation or removal. All nominees listed below are currently our directors and were previously elected by our stockholders at the 2017 Annual Meeting of Stockholders. It is our policy that directors are invited and expected to attend annual meetings. All directors, except Messrs. Kresa and Nordhoff, attended the 2017 Annual Meeting of Stockholders.
Directors are elected by a plurality of the votes properly cast in person or by proxy. The seven nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the seven nominees named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares may be voted for the election of a substitute nominee proposed by our Nominating and Corporate Governance Committee. Each person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be unable to serve. NOMINEES
The following is a brief biography of each nominee for director and a discussion of the specific experience, qualifications, attributes or skills of each nominee that led our Board of Directors to conclude that each nominee should serve as a member of the Board.
Name Age Position Held With the Company
Kent Kresa(1)(2) 80 Chairman of the Board of Directors
Michael E. Castagna, Pharm.D. 41 Chief Executive Officer and Director
Ronald J. Consiglio(2)(3) 74 Director
Michael A. Friedman, M.D.(1)(2) 74 Director
David H. MacCallum(3) 80 Director
Henry L. Nordhoff(3) 76 Director
James S. Shannon, M.D., MRCP (UK)(1) 61 Director (1) Member of the Compensation Committee.
(2) Member of the Nominating and Corporate Governance Committee.
(3) Member of the Audit Committee.
Kent Kresa has been a member of our Board of Directors since June 2004 and has served as Chairman of the Board since February 2017. From November 2011 until his appointment as our Chairman, Mr. Kresa served on our Board of Directors as our lead independent director. Mr. Kresa is Chairman Emeritus of Northrop Grumman Corporation, a defense company and from September 1990 until October 2003, he was also its Chairman. He also served as Chief Executive Officer of Northrop Grumman Corporation from January 1990 until March 2003 and as its President from 1987 until September 2001. From 2003 to August 2010, Mr. Kresa served as a director of General Motors Company (or its predecessor). From December 2005 to April 2010, Mr. Kresa served as a director of Avery Dennison Corporation. Mr. Kresa has been a member of the Caltech Board of Trustees since 1994. Mr. Kresa has served on the board of Fluor Corporation since 2003, and he also serves on the boards of several non-profit organizations and universities. As a graduate of Massachusetts Institute of Technology, he received a B.S. in 1959, an M.S. in 1961, and an E.A.A. in 1966, all in aeronautics and astronautics. The Board believes that Mr. Kresa’s business experience, including his experience as a director and executive officer of Northrop Grumman, and his service on other public company boards, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
Michael E. Castagna, Pharm.D. has served as our Chief Executive Officer and as one of our directors since May 2017. Mr. Castagna also served as a Corporate Vice President, Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined the Company, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Co. Before BMS, Mr. Castagna served as Vice President & Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences-Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. The Board believes that Mr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge. The Board believes that Mr. Consiglio’s knowledge and understanding of accounting and finance, his experience as a board member and executive officer at financial services firms, combined with his business acumen and judgment provide our Board with valuable accounting, financial and operational expertise and leadership and qualifies him to serve on our Board of Directors.
Michael A. Friedman, M.D. has been one of our directors since December 2003. In 2014, Dr. Friedman completed a decade of service as the President and Chief Executive Officer of the City of Hope National Medical Center. Previously, from September 2001 until April 2003, Dr. Friedman held the position of Senior Vice President of Research and Development, Medical and Public Policy, for Pharmacia Corporation and, from July 1999 until September 2001, was a senior vice president of Searle, a subsidiary of Monsanto Company. From 1995 until June 1999, Dr. Friedman served as Deputy Commissioner for Operations for the Food and Drug Administration, and was Acting Commissioner and Lead Deputy Commissioner from 1997 to 1998. He joined the board of Celgene Corporation in February 2011 and the board of Smith & Nephew plc in April 2013. Dr. Friedman received a bachelor of arts degree, magna cum laude, from Tulane University, New Orleans, Louisiana, and a doctorate in medicine from the University of Texas, Southwestern Medical School. The Board believes Dr. Friedman’s business experience, including his experience as an executive officer at biopharmaceutical companies and a leading clinical and research center specializing in cancer and diabetes, and his service at the Food and Drug Administration, combined with his business acumen and judgment provide our Board with valuable scientific and operational expertise and leadership and qualifies him to serve on our Board of Directors.
David H. MacCallum has been one of our directors since June 2004. Since 2002, Mr. MacCallum has served as the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001, he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was
Head of Health Care and Co-Head of Investment Banking. From 2005 to October 2010, Mr. MacCallum served as a director of Zymogenetics, Inc. From 2002 to 2008, he served as a director of Vital Signs, Inc. Mr. MacCallum received an A.B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst. The Board believes that Mr. MacCallum’s knowledge and understanding of accounting and finance, his business experience in the investment banking industry, combined with his business acumen and judgment provide our Board with valuable accounting, financial and operational expertise and leadership and qualifies him to serve on our Board of Directors.
Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University. The Board believes that Mr. Nordhoff’s business experience, including his experience as a director and executive officer at pharmaceutical and biotech companies, combined with his business acumen and judgment provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
James S. Shannon , M.D., MRCP (UK) rejoined our board in May 2015 after previously serving as a director from February 2010 until April 2012. From May 2012 until his retirement in April 2015, Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the position of Global Head of Pharma Development at Novartis AG, based in Basel, Switzerland from 2005 until 2008. After joining Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon led the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba-Geigy Ltd and Sandoz. Following the merger he was appointed Head of the Cardiovascular Strategic Team and subsequently became Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999, a position that he held until 2005 when he was appointed to Head Pharma Development. Between 2008 and joining GSK, Dr. Shannon served on the boards of a number of companies, including Biotie, Circassia, Crucell, Endocyte and MannKind. He also sat on the board of Cerimon Pharmaceuticals where he held the position of interim Chief Executive Officer and President from January 2009 until April 2010. He first entered the pharmaceutical industry in 1987 joining Sterling Winthrop Inc., working initially in Europe and subsequently in the USA, where he held positions of increasing responsibility in the management of research and development ultimately serving as Senior Vice-President, Clinical Development. Dr. Shannon is trained in Medicine and Cardiology. He received his undergraduate and postgraduate degrees at Queen’s University of Belfast and is a Member of the Royal College of Physicians (UK). The Board believes that Dr. Shannon’s business experience and his extensive experience in drug development, combined with his business acumen and judgment provide our Board with valuable scientific and operational expertise and leadership and qualifies him to serve on our Board of Directors.
|
|
|
Post by kc on Mar 28, 2018 14:40:06 GMT -5
Maybe they are exiting to go find a better target to make some money.
|
|
|
Post by kc on Mar 21, 2018 22:44:20 GMT -5
My endo practices at The International Diabetes Center in St. Louis Park, MN (suburb of Minneapolis). This was a site for a P3 trial of Bydureon that I participated in for 3 years. My doctor was not involved in the study. When Bydureon was approved she was reluctant to prescribe it because of the black box warning. I insisted and she wrote the script. I asked if she had heard of or seen a presentation on Afrezza and she said no. She said that pharma reps are not allowed to see the doctors. What a mess. Sad that this group is so closed minded. Interesting that doctor Kendall worked there back in 2008. Maybe he will target them.
|
|
|
Post by kc on Mar 21, 2018 11:59:49 GMT -5
Joey is just living the dream. Life is a Beach and he is enjoying it.
|
|
|
Post by kc on Mar 21, 2018 11:55:26 GMT -5
I am sticking with "lost". I think it will play better in the movie script. When you get a response of "what studies?" its clear Mike was not aware of all the studies. Why Matt did not sit Mike down 2 years ago and explain all of what had been done, I have no idea. Maybe Matt did not appreciate what Al did. Maybe he did and Mike never opened the box. The importance of the 118 study is huge and sets afrezza apart in diabetes treatment. All is good now and I would be surprised if Dr. Kendall is not already circulating some of Al's findings among his friends. Matt had to be overwhelmed with the passing of Al, getting Afrezza back from SNY, being CEO and CFO... Imagine SNY throwing Afrezza back to MNKD while MNKD being low on cash, heavily in debt, share price having been consequently pummeled, the need for just not a new but for a survival strategy while lacking the financial and management rescources to begin to do so. What did these studies mean to his CFO skills or to our prior CMO who’s strengths I believe were in oncology? no I believe it was more of the FDA LABEL issued that was the problem. That is what the FDA accepted. That has been our struggle. Now its up to Mike and Dr. Kendall to figure out how to use this data from the study in 2009. Al Mann always said that Afrezza was like a remission of diabetes. Need to get Key thought leaders to understand the old studies. They were not based on the current Technosphere device so again there is some relevance to getting acceptance today.
|
|
|
Post by kc on Mar 21, 2018 11:48:43 GMT -5
I for one hope you are right and thank God Mike found the lost studies and had the good sense to ask Dr. Kendall to review. The studies were never “lost”, they just weren’t utilized. What was previous managent thinking, ignoring the treasure trove of data they were sitting on? Hopefully there is enough lung safety data to go back to the FDA and eliminate or reduce the clinical safety trial they require. I think it was lack of a good CMO on board who understood how to analyze and go out to present studies the company has done in the past. I feel the gentle hand of Al Mann reaching from up above and giving them the push. But you also have folks like TCYOD and the JDRF folks including their President who is an Afrezza user. There are many thought leaders that need to step up and make their opinions heard. Dr. Kendall is just the man to get them on the same page. Let's hope that this thread title is correct.
I have used the term on Stocktwits and Twitter for a long time. That Afrezza is a Paradigm shift for diabetes treatment. Glad to see others using it too.
|
|
|
Post by kc on Mar 20, 2018 21:39:23 GMT -5
|
|
|
Post by kc on Mar 19, 2018 22:55:47 GMT -5
Winner winner chicken dinner. Or in monte Carlo it’s off to the craps tables.
|
|